… novel multifunctional agents, which in addition to decreasing … of MAO-B, an important caveat
for the neuroprotection effect … iron chelator drugs should comprise high selectivity for iron, …

… DFP is an iron chelator widely used for the treatment of thalassemia and other systemic iron
overload diseases, showing high affinity and selectivity for iron.29, 30 The characteristics of …

… of two objects: the familiar object A and a novel object B. These were placed in the … iron-induced
effects. Based on the present findings we suggest that DFP possesses neuroprotective …

… Novel iron chelating agents such as natural remedies are useful to decrease the side effects
of iron in the … A study investigated the neuroprotective and chelating capacities of green tea …

… that possess selective brain MAO A and B inhibitory moiety, iron … effect of the novel
neuroprotective multitarget nontoxic, … Molecular mechanism of neurorestorative activity of M30 and …

… and some other neuroprotective and neurorestorative effects [104]. Multifunctional iron
chelators … are required to develop iron-trapping agents that are highly selective, low affinity, BBB …

… and evaluating the effectiveness of neuroprotective therapy. Iron chelators have shown their
efficacy … Another novel chelator M30, has the ability of chelating iron, up-regulating hypoxia-…

… In iron-deficient cells, IRPs selectively bind IRE at 5 UTR of the mRNA coding for ferritin
and … by which it exerts neuroprotective activity is through decreasing redox-active iron [170]. …

… -selective MAO inhibitor that was previously demonstrated to possess anti-apoptotic and
neuroprotective activities … development of novel pharmacological treatment for ageing and AD. …

… Among these drugs, VAR10303 (VAR) possesses the neuroprotective N-propargyl moiety
of rasagiline and the antioxidant/radical-scavenging iron-chelating moiety of VK28 (Bar-Am et …